WaVe Life Sciences Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
317
- Stock Symbol
-
WVE
- Share Price
-
$3.13
- (As of Friday Closing)
WaVe Life Sciences General Information
Description
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Contact Information
Website
wavelifesciences.comCorporate Office
- 733 Concord Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- 733 Concord Avenue
- Cambridge, MA 02138
- United States
WaVe Life Sciences Stock Performance
As of 13-Nov-2026, WaVe Life Sciences’s stock price is $3.13. Its current market cap is $617M with 197M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.13 | $3.15 | $3.00 - $21.73 | $617M | 197M | 3.16M | -$1.08 |
WaVe Life Sciences Financials Summary
As of 30-Sep-2026, WaVe Life Sciences has a trailing 12-month revenue of $70.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 282,066 | 2,989,346 | 1,610,766 | 503,245 |
| Revenue | 70,921 | 42,727 | 108,302 | 113,305 |
| EBITDA | (201,307) | (195,526) | (88,345) | (48,984) |
| Net Income | (210,533) | (204,378) | (97,008) | (57,513) |
| Total Assets | 507,930 | 638,499 | 352,207 | 274,949 |
| Total Debt | 43,271 | 17,766 | 25,404 | 32,118 |
WaVe Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
WaVe Life Sciences Comparisons
Industry
Financing
Details
WaVe Life Sciences Competitors (75)
One of WaVe Life Sciences’s 75 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
WaVe Life Sciences Patents
WaVe Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213595-A1 | Oligonucleotide compositions and methods thereof | Pending | 03-Apr-2025 | ||
| WO-2026213596-A1 | Oligonucleotide compositions and methods thereof | Pending | 03-Apr-2025 | ||
| WO-2026213596-A8 | Oligonucleotide compositions and methods thereof | Pending | 03-Apr-2025 | ||
| WO-2026193338-A1 | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto | Pending | 13-Mar-2025 | ||
| WO-2026193338-A8 | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto | Pending | 13-Mar-2025 |
WaVe Life Sciences Signals
WaVe Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.36 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
WaVe Life Sciences FAQs
-
When was WaVe Life Sciences founded?
WaVe Life Sciences was founded in 2012.
-
Where is WaVe Life Sciences headquartered?
WaVe Life Sciences is headquartered in Cambridge, MA.
-
What is the size of WaVe Life Sciences?
WaVe Life Sciences has 317 total employees.
-
What industry is WaVe Life Sciences in?
WaVe Life Sciences’s primary industry is Drug Discovery.
-
Is WaVe Life Sciences a private or public company?
WaVe Life Sciences is a Public company.
-
What is WaVe Life Sciences’s stock symbol?
The ticker symbol for WaVe Life Sciences is WVE.
-
What is the current stock price of WaVe Life Sciences?
As of 13-Nov-2026 the stock price of WaVe Life Sciences is $3.13.
-
What is the current market cap of WaVe Life Sciences?
The current market capitalization of WaVe Life Sciences is $617M.
-
What is WaVe Life Sciences’s current revenue?
The trailing twelve month revenue for WaVe Life Sciences is $70.9M.
-
Who are WaVe Life Sciences’s competitors?
Dyne Therapeutics, Caribou Biosciences, Intellia Therapeutics, CRISPR Therapeutics, and Capricor Therapeutics are some of the 75 competitors of WaVe Life Sciences.
-
What is WaVe Life Sciences’s annual earnings per share (EPS)?
WaVe Life Sciences’s EPS for 12 months was -$1.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process